Physician profile
John A Billon
NPI 1083714653
$11,008.51
in general payments reported to CMS, 2019-2025
68 companies · $2,038 in 2025
The $2,038 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,243 · 2020: $1,433 · 2021: $1,749 · 2022: $1,386 · 2023: $1,711 · 2024: $1,449 · 2025: $2,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,197.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,029.39 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,446.49 | 2019-2025 | Ubrelvy, Vraylar, Creon |
| Lilly USA, LLC | $898.89 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $803.72 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $469.15 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $384.15 | 2019-2025 | Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $356.65 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $332.99 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $330.61 | 2019-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $323.59 | 2019-2024 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Abbott Laboratories | $263.03 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $253.12 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $233.84 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $228.19 | 2021-2024 | |
| Astellas Pharma US INC | $206.21 | 2023-2025 | Veozah |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Billon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.